UK markets open in 7 hours 7 minutes

Journey Medical Corporation (DERM)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.4400-0.1100 (-3.10%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.5500
Open3.5500
Bid3.3600 x 100
Ask3.5600 x 100
Day's range3.3500 - 3.6000
52-week range1.0200 - 8.1100
Volume84,124
Avg. volume150,678
Market cap68.707M
Beta (5Y monthly)0.81
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024

    Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ETSCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter

  • GlobeNewswire

    Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

    SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as t

  • GlobeNewswire

    Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024

    SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, announced today that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Pla